Pharmacological management of aseptic osteonecrosis in children

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1455-1462

  Petje, Gert ^a   Radler, Christof ^a   Aigner, Nicolas ^a   Manner, Hannes ^a   Kriegs Au, Gabriele ^a   Grill, Franz ^a  

^a ORTHOPAEDIC HOSPITAL SPEISING   (Austria)

Author keywords

Aseptic osteonecrosis in children; Pharmacological therapy of osteonecrosis

Indexed keywords

ACTIVIN; ALENDRONIC ACID; ANGIOGENIC FACTOR; ANGIOGENIN; BONE MORPHOGENETIC PROTEIN; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; ILOPROST; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 4; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SOMATOMEDIN B; SOMATOMEDIN C; STANOZOLOL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ASEPTIC NECROSIS; BODY TEMPERATURE DISORDER; BONE BLOOD FLOW; BONE MARROW DEPRESSION; BONE STRUCTURE; CHILD; CHILL; DIARRHEA; DISEASE DURATION; DRUG FEVER; DRUG MECHANISM; DRUG STRUCTURE; ENCHONDRAL OSSIFICATION; EXTRASYSTOLE; FATIGUE; FLUSHING; FRACTURE HEALING; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; MALAISE; MYELOPOIESIS; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL STRESS; RESTLESSNESS; REVIEW; SPINAL CORD ATROPHY; SWEATING; TACHYCARDIA; TRABECULAR BONE; VOMITING; WARMING;

CHILD; DISEASE PROGRESSION; HUMANS; ILOPROST; OSTEONECROSIS;

EID: 3543150224     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1455     Document Type: Review

References (55)

1. BERQUIST TH: Pelvis, hips, and thighs. In: MRI of the musculoskeletal system (2nd edn). Berquist TH (Ed.), Raven Press, New York, NY, USA (1990):149-194.
2. ARNOLDI CC: Vascular aspects of degenerative joint disorders. Acta Orthop. Scand. (1994) 65(Suppl. 261):1-82.
3. JONES JP: Fat embolism and osteonecrosis. Orthop. Clin. North Am. (1985) 16(4):595-633.
4. JONES JP: Intravascular coagulation and osteonecrosis. Clin. Orthop. (1992) 277:41-53.
5. WOOD JB, KLASSEN RA, PETERSON HA: Osteochondritis dissecans of the femoral head in children and adolescents; a report of 17 cases. J. Pediatr. Orthop. (1995) 15:313-316.
6. OHZONO K, TAKAOKA K, SAITO S, SAITO M, MATSUI M, ONO K: Intraosseous arterial architecture in nontraumatic avascular necrosis of the femoral head. Clin. Orthop. (1992) 277:79-88.
7. HUNGERFORD DS, ZIZIC TM: Pathogenesis of ischemic necrosis of the femoral head. In: The Hip. Proceedings of the 11th Open Scientific Meeting Of The Hip Society. CV Mosby, St. Louis, USA (1983):249-262.
8. HUNGERFORD DS: Pathogenetic considerations in ischemic necrosis of bone. Can. J. Surg. (1981) 24(6):583-590.
9. KIAER T, PEDERSEN NW, KRISTENS KD, STARKLINT H: Intraosseous pressure and oxygen tension in avascular necrosis and osteoarthrosis of the hip. J. Bone Joint Surg. (1990) 72:1023-1030.
10. STARKINT H, LAUSTEN GS, ARNOLDI CC: Microvascular obstruction in avascular necrosis. Acta Orthop. Scand. (1995) 66(1):9-12.
11. BERGER CE, KRONER A, STIEGLER H, ERDEL M, HAAS CA, ENGEL A: Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor. Clin. Orthop. (2002) 397:342-349.
12. LAROCHE M, JACQUEMIER JM, MONTANE DE LA ROUGE P, ARLET J, MAZIE'RES B: La nifédipine per os améliore les douleurs de l'osteonecrose de la tete fe morale. Rev. Rhum. Mal. Osteoartic. (1990) 57:669-670.
13. GLUECK CJ, FREIBERG R, GLUECK HI, TRACY T, STROOP D, WANG Y: Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am. J. Hematol. (1995) 48:213-220.
14. BOOS S, SIGMUND G, HUHLE P, NURBAKHSCH I: MR of transient osteoporosis. Primary diagnosis and follow-up after treatment. Fortschr. Geb. Rontgenstr. Nuklearmed. (1993) 158:2001-2006.
15. LAKHANPAL S, GRINSBURG WW, LUTHRA HS, HUNDER GG: Transient regional osteoporosis. Ann. Intern. Med. (1987) 106:444-450.
16. ABDEL-MAJID RM, MARSHALL JS: Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol. (2004) 172(2):1227-1236.
17. AVILES RJ, ANNEX BH, LEDERMAN RJ: Testing clinical therapeutic angigenesis using basic fibroblast growth factor. Br. J. Pharmacol. (2003)140(4):637-646.
18. WINET H, BAO JY, MOFFAT R: A control model for tibial cortex neovascularization in the bone chamber. J. Bone Miner. Res. (1990) 5:19-30.
19. YANG C, YANG S, DU J, LI J, XU W, XIONG Y: Vascular endothelial growth factor gene transfection to enhance the repair of avascular necrosis of the femoral head of rabbit. Chin. Med. J. (Engl.) (2003) 116(10):1544-1548.
20. BOLANDER ME: Regulation of fracture repair by growth factors. Proc. Soc. Exper. Biol. Med. (1992) 200:165-170.
21. HAUSCHKA PV, MAVRAKOS AE, IAFRATI MD, DOLEMAN SE, KLAGSBRUN M: Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem. (1986) 261:12665-12674.
22. BAZAN JF: Structural design and molecular evoution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA (1990) 87:6934-6938.
23. BEUTLER B, VAN HUFFEL C: Unraveling function in the TNF ligand and receptor families. Science (1994) 264:667-668.
24. JILKA RL: Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 257:88-91.
25. MANOLAGAS SC: Role of cytokines in bone resorption. Bone (1995) 17:63-67.
26. PACIFICI R, RIFAS L, MCCRACKEN R, AVIOLI LV: The role of interkeukin-1 in postmenopausal bone loss. Exp. Gerontol. (1990) 25:309-316.
27. GUENTHER HL, FLEISCH H, SORGENTER N: Endothelial cells in culture synthesize a potentbone cell active mitogen. Endocrinology (1986) 119:193-2001.
28. MUNDY GR: Regulation of bone formation by bone morphogenetic protein and other growth factors. Clin. Orthop. (1996) 323:24-28.
29. THALLER SR, HOYT J, TESLUK H, HOLMES R: Effect of insulin-like growth factor-1 o zygomatic arch bone regeneration: a preliminary histological and histometric study. Ann. Plast. Surg. (1993) 31:421-428.
30. THALLER SR, DART A, TESLUK H: The effects of insulin-like growth factor-1 on critical-size calvaria defects in Sprague-Dawley rats. Ann Plast Sug (1993) 31:429-433.
31. WILTON P: Treatment with recombinant human insulin-like growth factor 1 of children with growth hormone receptor deficiency (Laron syndrome). Acta Paediatr. (1992) 383(Suppl.): 137-142.
32. BECK LS, AMENTO EP, XU Y, DEGUZMAN L, LEE WP, NGUYEN T, GILLETT NA: TGF-beta 1 induces bone closure of skull defect: temporal dynamics of bone formation in defects exposed to rhTGF-beta 1. J. Bone Min. Res. (1993) 8:753-761.
33. LIND M, SCHUMACKER B, SOBALLE K, KELLER J, MELSEN F, BUNGER C: Transforming growth factor-betaenhance fracture healing in rabbit tibiae Acta Orthop. Scand. (1993) 64:553-556.
34. CENTRELLA M, MC CARTHY TL CANALIS E: Current concepts review Transforming growth factor-beta and remodelling of bone. J. Bone Joint Surg. Am. (1991) 73:1418-1428.
35. NIELSEN HM, ANDREASSEN TT, LEDET T, OXLUND: Local injection of TGF-beta increases the strength of tibial fractures in the rat. Acta Orthop. Scand. (1994) 65:37-41.
36. KAWAGUCHI H, KUROKAWA T, HANADA K, HIYAMA Y, TAMURA M, OGATA E, MATSUMOTO T: Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin diabetic rats. Endocrinology (1994) 135:774-7781.
37. ITO S, HATA T: Crystal structure of RANK ligand involved in bone metabolism. Vitam. Horm. (2004) 67:19-33.
38. URIST MR: Bone formation by autoinduction. Science (1965) 150:893-899.
39. REDDI AH, CUNNINGHAM NS: Bone induction by osteogenesis and bone morphogenetic proteins. Biomaterials (1990) 11:33.
40. COOK SD, BAFFES GC, WOLFE MW, SAMPATH TK, RUEGER DC, WHITECLOUD TS 3rd: The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J. Bone Joint Surg. Am. (1994) 76:827-838.
41. LANE JM, SANDHU HS: Current approaches to experimental bone grafting. Orthop. Clin. North Am. (1987) 18:213-225.
42. RIPAMONTI U, MA S, REDDI AH: The critical role of geometry of porous hydroxyapatite delivery systems in induction of bone by osteogenin, a bone morphogenetic protein. Matrix (1992) 12:202-212.
43. LINDHOLM TC: Bovine bone morphogenetic protein (bBMP/NCP)-induced repair of skull trephine defects in pigs. Clin. Orthop. (1994) 301:263.
44. SANDHU HS, KANIM LE, KABO JM et al.: Evaluation of rhBMP-2 with an OPLA carrier in a posterolateral (transvere process) spinal fusion model. Spine (1995) 20(24):2669-2682.
45. FERGUSON GM, MUTSCHLER TA: Ovine osteonecrosis of the femoral head: The role of bone morphogenic protein. Trans. Orthop. Res. Soc. (1995) 20:560.
46. SCHEDEL H, SCHNELLER A, VOGL T et al.: Dynamic magnetic resonance tomography (MRI): a follow-up study after femur core decompression and instillation of recombinant human bone morphogenetic protein-2 (rhBMP-2) in avascular femur head necrosis. Röntgenpraxis (2000) 53(1):16-24.
47. AIGNER N, PETJE G, STEINBÖCK G, SCHNEIDER W, KRASNY C, LANDSIEDL F: Treatment of bone marrow oedema of the talus with the prostacyclin analogue iloprost - an MRI controlled investigation of a new method. J. Bone Joint Surg (2001) 83(6):855-858.
48. AIGNER N, PETJE G, STEINBÖCK G, SCHNEIDER W, KRASNY C, LANDSIEDL F: Bone marrow edema of the forefoot after chevron osteotomy; a rare cause of metatarsalgia - a case report. Foot Ankle Int. (2002) 23(5):447-451.
49. AIGNER N, SCHNEIDER W, PETJE G, STEINBÖCK G, KRASNY C, LANDSIEDL F: Juvenile bone marrow edema of the acetabulum: treatment with Iloprost - a case report. J. Bone Joint Surg. Br. (2002) 84(7):1050-1052.
50. AIGNER N, MEIZER R, STOLZ G et al.: Iloprost for the treatment bof bone marrow edema in the hindfoot. Foot Ankle (2003) 8:683-693.
51. WATSON RM, ROACH NA, DALINKA MK: Avascular necrosis and bone marrow edema syndrom. Radiol. Clin. North Am. (2004) 42(1):207-219.
52. PETJE G, RADLER C, AIGNER N, KRIEGS-AU G, GANGER R, GRILL F: Aseptische Knochennekrose im Kindesalter Diagnose und Therapie. Orthopäde (2002) 31:1027-1038.
53. GRANT SM, GOA KL: Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs (1992) 43(6):889-924.
54. ASTRAND J, ASPENBERG P: Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone schamber study in rats. BMC Musculoskelet. Disorder (2002)3(1):19.
55. SENARATNE SG, PIRIANOV G, MANSI JL, ARNETT TR, COLSTON KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer (2000) 82:1459-1468.